journal article·2026-06Open access

Leveraging Artificial Intelligence and Large Language Models for Cancer Immunotherapy

Xinchao Wu, Mengtao Sun, Lusheng Li, Jieqiong Wang, Shibiao Wan

Advanced Science· Volume 13· Issue 35

Abstract

ABSTRACT Cancer immunotherapy, which leverages the immune system to combat tumor cells, has made significant advancements in oncology treatment in recent years. Yet significant challenges remain in predicting treatment responses and understanding mechanisms of resistance. Artificial intelligence (AI) and machine learning (ML) provide powerful tools to address these challenges, enabling breakthroughs in patient stratification, biomarker discovery, and treatment strategy optimization. While remarkable progress has been made in developing deep learning frameworks, including large language models (LLMs) to integrate the exponentially growing multi‐omics biomedical data for cancer immunotherapy, little effort has been made to systematically and comprehensively summarize these developments or critically evaluate their translational potential. To fill these gaps, this review comprehensively examines the current landscape and future directions of AI/ML applications in cancer immunotherapy. Specifically, we discuss four key areas in AI for cancer immunotherapy: (1) patient stratification, (2) biomarker discovery, (3) treatment strategy optimization, and (4) foundation models and LLMs for cancer immunotherapy. In addition, we also critically discuss current limitations and future directions for existing AI approaches for cancer immunotherapy, highlighting the actionable insights and roadmaps to accelerate the integration of AI/ML into precision cancer immunotherapy.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Cancer Immunotherapy and Biomarkers · vaccines and immunoinformatics approaches · Ferroptosis and cancer prognosis

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Genetics, Cell Biology, and Anatomy University of Nebraska Medical Center Omaha Nebraska USA

Department of Neurological Sciences University of Nebraska Medical Center Omaha Nebraska USA

Fred and Pamela Buffett Cancer Center University of Nebraska Medical Center Omaha Nebraska USA

Funding

National Science Foundation · NIH Office of the Director · National Cancer Institute · American Cancer Society · National Institute of General Medical Sciences · Child Health Research Institute, University of Nebraska Medical Center · Fred and Pamela Buffett Cancer Center

References (100+)

Show source-provided references
1. 10.1038/s41392-023-01521-510.1038/s41392-023-01521-5 ↗
2. 10.1038/s41467‐020‐17670‐y10.1038/s41467‐020‐17670‐y ↗
3. 10.1007/s00428‐018‐2484‐010.1007/s00428‐018‐2484‐0 ↗
4. 10.1016/j.semcancer.2019.08.00110.1016/j.semcancer.2019.08.001 ↗
5. 10.1186/s12943‐023‐01740‐y10.1186/s12943‐023‐01740‐y ↗
6. 10.1590/s1677‐5538.ibju.2020.068110.1590/s1677‐5538.ibju.2020.0681 ↗
7. 10.1038/s41571‐021‐00573‐210.1038/s41571‐021‐00573‐2 ↗
8. 10.1186/s12885‐021‐08997‐w10.1186/s12885‐021‐08997‐w ↗
9. 10.1038/s41417‐019‐0155‐110.1038/s41417‐019‐0155‐1 ↗
10. 10.3389/fimmu.2022.88271810.3389/fimmu.2022.882718 ↗
11. 10.1016/j.ctrv.2018.02.00410.1016/j.ctrv.2018.02.004 ↗
12. 10.1016/j.adro.2018.08.01810.1016/j.adro.2018.08.018 ↗
13. 10.1038/s41573‐022‐00615‐z10.1038/s41573‐022‐00615‐z ↗
14. 10.1016/j.prp.2021.15372310.1016/j.prp.2021.153723 ↗
15. 10.1056/NEJMoa240741710.1056/NEJMoa2407417 ↗
16. 10.1056/NEJMoa150182410.1056/NEJMoa1501824 ↗
17. 10.1056/NEJMoa151066510.1056/NEJMoa1510665 ↗
18. 10.1007/s12032‐025‐02822‐110.1007/s12032‐025‐02822‐1 ↗
19. 10.1056/NEJMoa170744710.1056/NEJMoa1707447 ↗
20. 10.1158/0008‐5472.CAN‐21‐110910.1158/0008‐5472.CAN‐21‐1109 ↗
21. 10.1038/s41571‐022‐00719‐w10.1038/s41571‐022‐00719‐w ↗
22. 10.1038/s41571‐020‐00449‐x10.1038/s41571‐020‐00449‐x ↗
23. 10.1038/s41591‐018‐0008‐810.1038/s41591‐018‐0008‐8 ↗
24. 10.1016/j.ccell.2023.01.01010.1016/j.ccell.2023.01.010 ↗
25. 10.1182/blood‐2020‐13765010.1182/blood‐2020‐137650 ↗
26. 10.1016/j.ccell.2021.07.00410.1016/j.ccell.2021.07.004 ↗
27. 10.1038/s41392‐021‐00729‐710.1038/s41392‐021‐00729‐7 ↗
28. 10.18203/2349‐3259.ijct2016140810.18203/2349‐3259.ijct20161408 ↗
29. 10.1093/bib/bbab49110.1093/bib/bbab491 ↗
30. 10.1038/s41592‐018‐0229‐210.1038/s41592‐018‐0229‐2 ↗
31. 10.1038/s41592‐019‐0619‐010.1038/s41592‐019‐0619‐0 ↗
32. 10.1016/j.bbcan.2021.18857210.1016/j.bbcan.2021.188572 ↗
33. 10.1038/s41592‐024‐02523‐z10.1038/s41592‐024‐02523‐z ↗
34. 10.1002/cac2.1237310.1002/cac2.12373 ↗
35. Advancing Precision Medicine: the Transformative Role of Artificial Intelligence in Immunogenomics, Radiomics, and Pathomics for Biomarker Discovery and Immunotherapy Optimization
36. 10.1038/s41598‐024‐58684‐610.1038/s41598‐024‐58684‐6 ↗
37. 10.1007/s10238‐024‐01324‐010.1007/s10238‐024‐01324‐0 ↗
38. 10.1038/s41586‐024‐08378‐w10.1038/s41586‐024‐08378‐w ↗
39. 10.1038/s41592‐025‐02814‐z10.1038/s41592‐025‐02814‐z ↗
40. 10.1186/s13059‐025‐03574‐x10.1186/s13059‐025‐03574‐x ↗
41. 10.1038/s41592‐025‐02909‐710.1038/s41592‐025‐02909‐7 ↗
42. N.ParkandJ. H.Lee “A Systematic Multi‐LLM AI Framework for Immunotherapy Biomarker Discovery and Target Identification ” preprint BioRxiv 2025 https://doi.org/10.1101/2025.06.10.658988.10.1101/2025.06.10.658988 ↗
43. 10.1038/s44386-025-00009-210.1038/s44386-025-00009-2 ↗
44. 10.3389/fimmu.2024.128194010.3389/fimmu.2024.1281940 ↗
45. 10.1186/s12967‐023‐04004‐x10.1186/s12967‐023‐04004‐x ↗
46. 10.1186/s13045‐023‐01456‐y10.1186/s13045‐023‐01456‐y ↗
47. 10.1038/nmeth.264510.1038/nmeth.2645 ↗
48. 10.1371/journal.pcbi.100425910.1371/journal.pcbi.1004259 ↗
49. 10.2202/1544-6115.147010.2202/1544-6115.1470 ↗
50. 10.1109/5.72679110.1109/5.726791 ↗
51. 10.1038/323533a010.1038/323533a0 ↗
52. Vaswani A. · 2017
53. 10.21037/atm.2020.03.19410.21037/atm.2020.03.194 ↗
54. 10.1038/nrc.2016.12610.1038/nrc.2016.126 ↗
55. 10.1158/1078‐0432.CCR‐15‐287910.1158/1078‐0432.CCR‐15‐2879 ↗
56. 10.1038/s41587‐021‐01070‐810.1038/s41587‐021‐01070‐8 ↗
57. 10.1016/j.semcancer.2022.11.00810.1016/j.semcancer.2022.11.008 ↗
58. 10.3389/fonc.2021.78251510.3389/fonc.2021.782515 ↗
59. 10.1038/s41591‐019‐0462‐y10.1038/s41591‐019‐0462‐y ↗
60. 10.1016/j.bspc.2025.10774210.1016/j.bspc.2025.107742 ↗
61. 10.3389/fimmu.2022.109882510.3389/fimmu.2022.1098825 ↗
62. 10.1093/bib/bbab45410.1093/bib/bbab454 ↗
63. 10.3389/fgene.2022.85475210.3389/fgene.2022.854752 ↗
64. 10.1016/j.fmre.2022.06.00810.1016/j.fmre.2022.06.008 ↗
65. 10.1186/s12859‐024‐05749‐y10.1186/s12859‐024‐05749‐y ↗
66. 10.1016/j.eswa.2023.12004710.1016/j.eswa.2023.120047 ↗
67. 10.1186/s12864‐024‐09985‐710.1186/s12864‐024‐09985‐7 ↗
68. 10.1016/j.cmpb.2024.10847810.1016/j.cmpb.2024.108478 ↗
69. 10.1158/2159‐8290.CD‐24‐148810.1158/2159‐8290.CD‐24‐1488 ↗
70. 10.1016/S1470‐2045(20)30328‐410.1016/S1470‐2045(20)30328‐4 ↗
71. 10.1038/s41416‐021‐01413‐x10.1038/s41416‐021‐01413‐x ↗
72. 10.1093/annonc/mdz00310.1093/annonc/mdz003 ↗
73. How to Differentiate Pseudoprogression from True Progression in Cancer Patients Treated with Immunotherapy
74. 10.1038/s43018‐024‐00772‐710.1038/s43018‐024‐00772‐7 ↗
75. 10.1007/s13167‐023‐00327‐310.1007/s13167‐023‐00327‐3 ↗
76. 10.1186/s12885‐025‐14012‐310.1186/s12885‐025‐14012‐3 ↗
77. 10.1038/s41467‐023‐40890‐x10.1038/s41467‐023‐40890‐x ↗
78. 10.1093/bib/bbad02310.1093/bib/bbad023 ↗
79. W.Shen T. H.Nguyen M. M.Li et al. “Generalizable AI Predicts Immunotherapy Outcomes across Cancers and Treatments ” preprint medRxiv 2025 https://doi.org/10.1101/2025.05.01.25326820.10.1101/2025.05.01.25326820 ↗
80. 10.1200/PO‐25‐0017210.1200/PO‐25‐00172 ↗
81. 10.1186/s13046‐024‐03153‐110.1186/s13046‐024‐03153‐1 ↗
82. 10.1016/j.annonc.2023.11.00810.1016/j.annonc.2023.11.008 ↗
83. 10.1158/1078‐0432.CCR‐25‐088910.1158/1078‐0432.CCR‐25‐0889 ↗
84. 10.3390/cancers1413312710.3390/cancers14133127 ↗
85. 10.1002/advs.20240106110.1002/advs.202401061 ↗
86. 10.1021/acs.jproteome.4c0088210.1021/acs.jproteome.4c00882 ↗
87. 10.1093/bib/bbad48710.1093/bib/bbad487 ↗
88. 10.1158/2326‐6066.CIR‐23‐087310.1158/2326‐6066.CIR‐23‐0873 ↗
89. 10.1016/S1470‐2045(18)30700‐910.1016/S1470‐2045(18)30700‐9 ↗
90. 10.1016/S0140‐6736(19)32591‐710.1016/S0140‐6736(19)32591‐7 ↗
91. 10.1056/NEJMoa161368310.1056/NEJMoa1613683 ↗
92. 10.1093/annonc/mdz12710.1093/annonc/mdz127 ↗
93. 10.1016/j.eururo.2017.02.01010.1016/j.eururo.2017.02.010 ↗
94. 10.1200/JCO.21.0017410.1200/JCO.21.00174 ↗
95. 10.1016/j.annonc.2023.10.12510.1016/j.annonc.2023.10.125 ↗
96. 10.1158/1535‐7163.MCT‐14‐098310.1158/1535‐7163.MCT‐14‐0983 ↗
97. 10.1016/j.ccell.2020.10.00110.1016/j.ccell.2020.10.001 ↗
98. 10.3389/fimmu.2023.126520210.3389/fimmu.2023.1265202 ↗
99. 10.1016/j.cell.2021.09.01410.1016/j.cell.2021.09.014 ↗
100. 10.1186/s12967‐023‐04633‐210.1186/s12967‐023‐04633‐2 ↗